poisar

Stocks · News reference

Ascentage Pharma Stock Could More Than Double: Analyst

BenzingaVandana Singh

William Blair sees major upside for Ascentage Pharma stock as the cancer drug developer approaches three pivotal trial results in 2027.

Reference Details

Connected Markets

Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.

Source
benzinga
Observed
Checked
Cadence
Captured once, then retained as an archive reference
Status
fresh

Keep reading

  1. Globenewswire IncAmerican Academy Of Sleep Medicine

    AASM releases roadmap to improve women’s sleep health

    The American Academy of Sleep Medicine released a comprehensive report and multiyear roadmap to improve women's sleep health, identifying priority areas including fertility, pregnancy, postpartum health, menopausal transitions, and sleep disorders. The report highlights gaps in research, clinical care, and policy, calling for increased clinical trial representation, research funding, and tailored interventions for women.

  2. Globenewswire IncAscentage Pharma Group International

    Ascentage Pharma Announces Inclusion of Lisaftoclax in China's 2026 National Reimbursement Drug List and Successful Renewal of Coverage for Olverembatinib

    Ascentage Pharma announced that lisaftoclax has been included in China's 2026 National Reimbursement Drug List (NRDL) for treating chronic lymphocytic leukemia/small lymphocytic lymphoma, while olverembatinib successfully renewed its NRDL coverage for chronic myeloid leukemia treatment. Both approvals take effect January 1, 2027, and represent all approved indications for both drugs now being covered by the NRDL, significantly improving patient access and affordability in China.

  3. Zacks Investment ResearchNa

    HRMY Q3 Earnings Miss Estimates on Higher Costs Despite Wakix Growth

    Harmony Biosciences reported Q3 EPS of 81 cents, missing consensus estimates of $1.00, despite 12% revenue growth to $269 million. Higher R&D spending, a $25 million MSN milestone charge, and royalty expenses pressured profitability. The company reaffirmed its 2026 Wakix revenue guidance of $1-$1.04 billion, supported by sustained patient demand and 400 net patient additions. The pipeline includes promising Phase I results for BP-205 and ongoing late-stage studies for pitolisant formulations and epilepsy programs.